Lord, Abbett & Co’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-66,423
Closed -$2.6M 820
2018
Q4
$2.6M Sell
66,423
-33,561
-34% -$1.46M 0.01% 723
2018
Q3
$5.45M Sell
99,984
-1,095,510
-92% -$74.9M 0.02% 719
2018
Q2
$98.9M Buy
1,195,494
+892,645
+295% +$68.9M 0.29% 84
2018
Q1
$20.2M Buy
302,849
+5,957
+2% +$344K 0.06% 468
2017
Q4
$15.3M Sell
296,892
-766,659
-72% -$55.1M 0.04% 535
2017
Q3
$94.8M Buy
1,063,551
+604,765
+132% +$45.9M 0.28% 91
2017
Q2
$27.4M Sell
458,786
-35,222
-7% -$1.97M 0.08% 364
2017
Q1
$26.4M Sell
494,008
-70,738
-13% -$4.2M 0.08% 381
2016
Q4
$28.2M Sell
564,746
-518,771
-48% -$27.8M 0.09% 336
2016
Q3
$65.1M Sell
1,083,517
-81,690
-7% -$4.71M 0.2% 157
2016
Q2
$59.6M Buy
1,165,207
+753,377
+183% +$32.2M 0.19% 155
2016
Q1
$12.2M Sell
411,830
-239,665
-37% -$7.56M 0.04% 524
2015
Q4
$29.5M Buy
651,495
+22,724
+4% +$1.19M 0.09% 350
2015
Q3
$26.2M Buy
628,771
+6,651
+1% +$347K 0.08% 356
2015
Q2
$37.5M Buy
622,120
+87,199
+16% +$5.77M 0.1% 330
2015
Q1
$41.5M Buy
+534,921
New +$30.8M 0.1% 304

Other funds holding ONCE

Lord, Abbett & Co's ONCE Position: Q1 2019 in Review

Lord, Abbett & Co sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q1 2019, closing a stake of 66,423 shares — an estimated $2.6M sold.

Lord, Abbett & Co first reported a position in ONCE in Q1 2015 and held it in 16 quarters. The position peaked at $98.9M in Q2 2018. 199 funds tracked by Wall St. Rank hold ONCE as of Q1 2019.

  • Lord, Abbett & Co reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Lord, Abbett & Co sold 66,423 Spark Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $2.6M.
  • Lord, Abbett & Co first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 16 quarters.
  • Lord, Abbett & Co's Spark Therapeutics, Inc. Common Stock position peaked at $98.9M in Q2 2018.
  • 199 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Lord, Abbett & Co's 13F filing for Q1 2019, filed 15 May 2019.